Skip to main content
UniHealth

Doctor search

Lawrence D Recht, MD

Neurology · Stanford

NPI 1417007469

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
18
4 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

18 plans · 4 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Recht’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

18 of 18 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
Anthem Full Dual Advantage Aligned (HMO D-SNP)Anthem Blue CrossListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence G87020 · Current

Licensed to practise in California · since 2003 · expires 2027-08-31 · Columbia University College of Physicians and Surgeons.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$36,575

Medicare paid this office $36,575 for 198 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)57$8,395$115
Return visit (30+ min)71$7,336$83
Return visit (30+ min)45$6,796$111
New patient visit (60+ min)40$6,010$150
Long return visit (40+ min)22$4,721$169

Who their Medicare patients are

198 Original Medicare patients in 2024. Average age 70 · Under 65 22% · 85 and older 11% · Women 49% · Also on Medicaid 30% · Health risk score 1.66. Above the middle of the specialty; the typical neurology clinician is at 1.61.

Conditions among them: High blood pressure 64% · Depression 32% · Stroke 27% · Diabetes 25% · Coronary heart disease 21% · Chronic kidney disease 18% · Cancer 17% · Atrial fibrillation 14% · Dementia 14% · Heart failure 13% · COPD 10%.

The office billed $124,784, Medicare allowed $49,684 and paid $36,575; for 322 services of 11 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024198322701.66$124,784$36,575
2023126158701.61$60,875$15,797
2022226380691.81$152,272$41,512
2021151272671.90$119,313$29,702
202085194641.88$77,098$16,124
2019117212662.16$33,728$18,345
2018116269661.86$38,999$24,315
2017115253661.77$57,417$21,284
2016104225642.00$56,339$19,847
2015112301652.06$83,456$25,997
2014154362671.95$101,047$30,642
2013125302651.65$84,208$24,661

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 3 services

Original Medicare services billed in 2023
Return visit (30+ min)64$5,542$76
Long return visit (40+ min)41$5,505$120
New patient visit (60+ min)19$2,679$141

2022: 3 services

Original Medicare services billed in 2022
Long return visit (40+ min)98$17,661$124
Return visit (30+ min)117$13,589$84
New patient visit (60+ min)48$7,327$153

2021: 3 services

Original Medicare services billed in 2021
Long return visit (40+ min)72$13,714$126
Return visit (30+ min)75$9,478$82
New patient visit (60+ min)33$5,390$163

2020: 2 services

Original Medicare services billed in 2020
Long return visit (40+ min)46$7,906$100
Return visit (30+ min)57$5,500$64

2019: 3 services

Original Medicare services billed in 2019
Long return visit (40+ min)53$7,827$97
Return visit (30+ min)68$6,172$63
New patient visit (60+ min)20$2,752$138

2018: 3 services

Original Medicare services billed in 2018
Long return visit (40+ min)78$15,873$96
Return visit (30+ min)54$4,349$60
New patient visit (60+ min)23$3,147$137

2017: 3 services

Original Medicare services billed in 2017
Long return visit (40+ min)59$9,941$91
Return visit (30+ min)64$6,591$61
New patient visit (60+ min)25$3,471$139

2016: 3 services

Original Medicare services billed in 2016
Long return visit (40+ min)57$7,630$98
Return visit (30+ min)60$7,506$66
New patient visit (60+ min)25$3,743$150

2015: 4 services

Original Medicare services billed in 2015
Long return visit (40+ min)50$9,037$92
Return visit (30+ min)63$7,264$59
Initial hospital care with moderate level of medical decision making at least 75 minutes17$3,264$181
New patient visit (60+ min)17$2,548$150

2014: 5 services

Original Medicare services billed in 2014
Return visit (30+ min)83$10,712$62
Long return visit (40+ min)56$7,934$90
New patient visit (60+ min)26$3,428$132
Initial hospital care with moderate level of medical decision making at least 75 minutes19$3,418$180
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes11$1,339$122

2013: 4 services

Original Medicare services billed in 2013
Return visit (30+ min)77$9,780$60
Long return visit (40+ min)40$5,704$91
Initial hospital care with moderate level of medical decision making at least 75 minutes20$3,499$175
New patient visit (60+ min)21$2,994$143

Medicaid work

$1,354 in 2024

Medicaid paid $1,354 for 26 billed services this clinician did in 2024, up to 12 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Return visit (30+ min)26$1,354
Medicaid work by year
202426112$1,354
202345215$2,753
202299216$4,460
201812112$425
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)30$1,597
Return visit (30+ min)15$1,156

2022

Largest Medicaid services in 2022
Return visit (30+ min)56$2,436
Long return visit (40+ min)43$2,024

2018

Largest Medicaid services in 2018
Long return visit (40+ min)12$425

Drugs they prescribed that Part D paid

$2,709

Pharmacies billed $2,709 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 18% of their Part D prescriptions (11 of 61) in 2024. A higher opioid share than 9 in 10 peers; the typical neurology clinician is at 0%.

61 generic and 0 brand-name prescriptions · $2,709 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Levetiracetam16$1,810$113

Year by year

Part D prescribing by year
2024612218% (11)0%$2,709
202343210% (0)None$76,066
202210336None15%$189,728
202113835None28%$328,474
202020942None33%$370,977
201918735None14%$125,607
2018266455% (12)22%$198,385
201728239None23%$237,437
201626144None15%$43,668
201529942None18%$38,045
2014421634% (16)19%$66,837
201326042None12%$11,848

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2022: 2 drugs

Part D drugs prescribed in 2022
Gamunex-CImmune globulin12$160,062$13,339
LevetiracetamNone23$2,888$126

2021: 4 drugs

Part D drugs prescribed in 2021
HizentraImmune globulin24$164,325$6,847
Gamunex-CImmune globulin12$157,083$13,090
LevetiracetamNone29$2,735$94
DexamethasoneNone13$280$22

2020: 7 drugs

Part D drugs prescribed in 2020
HizentraImmune globulin30$164,704$5,490
Gamunex-CImmune globulin13$153,789$11,830
VimpatNone15$20,735$1,382
LevetiracetamNone34$1,684$50
DexamethasoneNone12$306$25
Citalopram HbrNone20$164$8
LamotrigineNone12$50$4

2019: 6 drugs

Part D drugs prescribed in 2019
HizentraImmune globulin12$55,508$4,626
LevetiracetamNone41$1,696$41
Phenytoin Sodium ExtendedNone13$475$37
DuloxetineNone13$270$21
OndansetronNone15$239$16
LamotrigineNone13$28$2

2018: 6 drugs

Part D drugs prescribed in 2018
HizentraImmune globulin39$177,795$4,559
LevetiracetamNone41$1,325$32
Phenytoin Sodium ExtendedNone20$798$40
DexamethasoneNone24$459$19
LamotrigineNone13$150$12
FluoxetineNone12$15$1

2017: 9 drugs

Part D drugs prescribed in 2017
HizentraImmune globulin30$171,879$5,729
VimpatNone13$10,382$799
LevetiracetamNone54$2,227$41
Levetiracetam ErNone11$1,272$116
LamotrigineNone13$382$29
DexamethasoneNone15$341$23
Phenytoin Sodium ExtendedNone13$309$24
OndansetronNone17$146$9
FluoxetineNone13$16$1

2016: 6 drugs

Part D drugs prescribed in 2016
Vimpat11$7,119$647
Levetiracetam62$3,586$58
Tegretol Xr14$3,274$234
Dexamethasone26$757$29
Ondansetron17$361$21
Citalopram Hbr29$170$6

2015: 10 drugs

Part D drugs prescribed in 2015
Vimpat23$12,425$540
Levetiracetam73$3,335$46
Tegretol Xr15$2,750$183
Dexamethasone25$470$19
Lamotrigine20$266$13
Ondansetron13$232$18
Citalopram Hbr23$133$6
Famotidine12$126$11
Carisoprodol12$124$10
Lisinopril12$78$7

2014: 13 drugs

Part D drugs prescribed in 2014
Enoxaparin13$16,707$1,285
Vimpat25$12,115$485
Namenda13$3,676$283
Levetiracetam71$2,747$39
Tegretol Xr18$1,499$83
Lomustine12$1,100$92
Dexamethasone43$952$22
Ondansetron17$589$35
Citalopram Hbr33$194$6
Lamotrigine18$179$10
Hydrocodone-Acetaminophen13$159$12
Carisoprodol11$139$13
Lisinopril15$96$6

2013: 8 drugs

Part D drugs prescribed in 2013
Vimpat12$5,091$424
Levetiracetam61$2,613$43
Ondansetron25$550$22
Lamotrigine14$308$22
Baclofen12$127$11
Pantoprazole12$80$7
Citalopram Hbr11$46$4
Lorazepam11$37$3

Money from drug and device companies

$14 in 2020

A payment is not proof that care is biased.

Payments by company
AlmirallSeysara$14
1 payment
  • Meals for Seysara · 2020-11-10 · $14
See the published payment
Every published payment
AlmirallMeals · 2020-11-10Seysara$14

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
SANOFI US SERVICES INC. · A Phase II Follow-Up Study To Determine Whether the Addition of Whole Brain Radiotherapy (Wbrt) To Standard Temozolomide Chemo-Radiotherapy Will Improve Overall Survival in Patients With Newly Diagnos · 2019Their institution$2,811,353
SANOFI US SERVICES INC. · A Phase II Follow-Up Study To Determine Whether the Addition of Whole Brain Radiotherapy (Wbrt) To Standard Temozolomide Chemo-Radiotherapy Will Improve Overall Survival in Patients With Newly Diagnos · 2020Their institution$1,898,627
SANOFI US SERVICES INC. · A Phase II Followup Study To Determine Whether the Addition of Whole Brain Radiotherapy (Wbrt) To Standard Temozolomide Chemoradiotherapy Will Improve Overall Survival in Patients With Newly Diagnosed Glioblastoma (Gbm) Treated With 4 Weeks of Continuous Infusion Plerixafor · 2021Their institution$885,562
SANOFI US SERVICES INC. · A Phase II Follow-Up Study To Determine Whether the Addition of Whole Brain Radiotherapy (Wbrt) To Standard Temozolomide Chemo-Radiotherapy Will Improve Overall Survival in Patients With Newly Diagnosed Glioblastoma (Gbm) · 2020Their institution$631,947
GENZYME CORPORATION · A Phase II Follow-Up Study To Determine Whether the Addition of Whole Brain Radiotherapy (Wbrt) To Standard Temozolomide Chemo-Radiotherapy Will Improve Overall Survival in Patients With Newly Diagnosed Glioblastoma (Gbm) Treated With 4 Weeks of Continuous Infusion Plerixafor · 2020Their institution$126,000
GENZYME CORPORATION · A Phase II Follow-Up Study To Determine Whether the Addition of Whole Brain Radiotherapy (Wbrt) To Standard Temozolomide Chemo-Radiotherapy Will Improve Overall Survival in Patients With Newly Diagnosed Glioblastoma (Gbm) Treated With 4 Weeks of Continuous Infusion Plerixafor · 2019Their institution$49,500
SANOFI US SERVICES INC. · A Phase II Follow-Up Study To Determine Whether the Addition of Whole Brain Radiotherapy (Wbrt) To Standard Temozolomide Chemo-Radiotherapy Will Improve Overall Survival in Patients With Newly Diagnosed Glioblastoma (Gbm) Treated With 4 Weeks of Continuou · 2025Their institution$45,000
SANOFI-AVENTIS U.S. LLC · A Phase II Follow-Up Study To Determine Whether the Addition of Whole Brain Radiotherapy (Wbrt) To Standard Temozolomide Chemo-Radiotherapy Will Improve Overall Survival in Patients With Newly Diagnosed Glioblastoma (Gbm) Treated With 4 Weeks of Continuou · 2025Their institution$45,000
SANOFI US SERVICES INC. · A Phase II Follow-Up Study To Determine Whether the Addition of Whole Brain Radiotherapy (Wbrt) To Standard Temozolomide Chemo-Radiotherapy Will Improve Overall Survival in Patients With Newly Diagnosed Glioblastoma (Gbm) Treated With 4 Weeks of Continuou · 2024Their institution$30,000
SANOFI US SERVICES INC. · A Phase II Follow-Up Study To Determine Whether the Addition of Whole Brain Radiotherapy (Wbrt) To Standard Temozolomide Chemo-Radiotherapy Will Improve Overall Survival in Patients With Newly Diagnosed Glioblastoma (Gbm) Treated With 4 Weeks of Continuou · 2023Their institution$24,750
Novocure Inc. · Ef-41/?Keynote D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma (Ef-41) · 2025Their institution$15,024
Novocure GmbH · Ef-41/?Keynote D58: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune (Ttfields, 200 Khz) Concomitant With Maintenance Temozolomide and Pembrolizumab Versus Optune Concomitant With Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma · 2025Their institution$14,400
Acerta Pharma LLC · A Multicenter Open Label Study of Acp196 in Subjects With Recurrent Glioblastoma Multiforme · 2019Their institution$512

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1417007469
Licence
CA G87020California G87020: Current · expires 2027-08-31
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Neurology (2084N0400X)
Mailing address
875 Blake Wilbur Dr., Rm Cc2221, Stanford, CA, 94305
NPI first listed
2007-01-11
NPI last updated
2011-10-25

This is when the NPI record was last certified, not a medical board exam.